ALFACELL CORP
10-K, EX-23.1, 2000-10-30
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: ALFACELL CORP, 10-K, EX-10.21, 2000-10-30
Next: ALFACELL CORP, 10-K, EX-99.1CHARTER, 2000-10-30





                                                                    Exhibit 23.1



                          Independent Auditors' Consent



The Board of Directors
Alfacell Corporation:


We consent to  incorporation  by reference in the  registration  statements (No.
33-81308) on Form S-8 and (Nos. 333-29313 and 333-48975) on Form S-3 of Alfacell
Corporation of our report dated October 4, 2000,  relating to the balance sheets
of Alfacell Corporation as of July 31, 2000 and 1999, and the related statements
of operations, stockholders' equity (deficiency), and cash flows for each of the
years in the  three-year  period  ended July 31, 2000 and the period from August
24, 1981 (date of inception) to July 31, 2000,  which report appears in the July
31, 2000 annual  report on Form 10-K of Alfacell  Corporation.  Our report dated
October 4, 2000, as it relates to the financial  statements  for the period from
August 24, 1981 (date of  inception) to July 31, 2000, is based on the report of
other auditors as to the amounts included therein for the period from August 24,
1981 (date of inception) to July 31, 1992.

Our report dated October 4, 2000 contains an  explanatory  paragraph that states
that the Company has suffered  recurring losses from  operations,  has a working
capital deficit and has limited liquid resources which raise  substantial  doubt
about its ability to continue as a going  concern.  The financial  statements do
not  include  any  adjustments  that  might  result  from  the  outcome  of that
uncertainty.



/s/ KPMG LLP
KPMG LLP

Short Hills, New Jersey
October 30, 2000





© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission